Tactile Systems Technology, Inc. (NASDAQ:TCMD) is set to announce third quarter earning results on Monday 2nd November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, TCMD to report 3Q20 loss of $ 0.06 per share.
For the full year, analysts anticipate top line of $ 184.43 million, while looking forward to loss of $ 0.63 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 227.50 million ~ $ 230.50 million
Click Here For More Historical Outlooks Of Tactile Systems Technology, Inc.
Previous Quarter Performance
Tactile Systems Technology, Inc. revealed loss for the second quarter of $ 0.51 per share, from the revenue of $ 35.10 million. The quarterly revenues down 22.35 percent compared with the same quarter last year. Street analysts expected Tactile Systems Technology, Inc. to report loss of $ 0.22 per share on revenue of $ 36.90 million for the second quarter. The bottom line results missed street analysts by $ 0.29 or 131.82 percent, at the same time, top line results fell short of analysts by $ 1.8 million or 4.88 percent.
Stock Performance
On Friday, shares of Tactile Systems Technology, Inc. has traded high as $ 38.49 and has cracked $ 35.93 on the downward trend, reaching $ 36.58 with volume of 270.00 thousand shares.
According to the previous trading day, closing price of $ 36.58, representing a 30.00 % increase from the 52 week low of $ 29.47 and a 46.53 % decrease over the 52 week high of $ 71.65.
The company has a market capital of $ 710.13 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Tactile Systems Technology, Inc. will be hosting a conference call at 5:00 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.tactilemedical.com
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices for the treatment of chronic diseases in the United States. The company offers Flexitouch system, an at-home solution for lymphedema patients; and ACTitouch system, a home-based solution for chronic venous insufficiency patients. It also provides Entré System, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and Airwear Gradient Compression Wrap management of venous insufficiency, venous hypertension, venous ulcerations and lymphedema under the trade name Aero-Wrap.
